{
    "doi": "https://doi.org/10.1182/blood.V122.21.2986.2986",
    "article_title": "Evaluating Risk Factors and Outcomes For Clostridium Difficile Infection (CDI) In Stem Cell Transplant (SCT) Recipients ",
    "article_date": "November 15, 2013",
    "session_type": "901. Health Services and Outcomes Research: Poster II",
    "abstract_text": "Introduction Clostridium difficile infections (CDI) are the leading cause of infectious diarrhea among pts undergoing stem cell transplantation (SCT). Data from large pt samples evaluating the trends, risk factors, hospitalization outcomes are lacking. We have analyzed the Nationwide Inpt Sample (NIS) database to evaluate the trends in the incidence and the impact of CDI on hospitalization outcomes among SCT recipients. Methods We used the NIS database to obtain the hospitalization data for primary procedures of autologous and allogeneic SCT between 01/2001 until 12/2010. We performed separate multivariate logistic regression analyses to evaluate risk factors of CDI in SCT pts and hospitalization outcomes including length of stay (LOS), in-hospital mortality (IHM) and hospitalization charges. Comorbidites were identified using software that created measures reported by Elixhauser et al. Results The incidence of CDI among transplant pts has remained relatively stable over time ( Fig 1 ), with a higher cumulative incidence of CDI among recipients of allogeneic grafts (allogeneic vs. autologous SCT: 8.29% vs. 5.63%; p<0.001). There was an association between CDI and the presence of multiple comorbidities among autologous SCT pts (p=0.05), and a similar trend was seen in allogeneic transplant pts. Mean LOS (CDI vs. none: autologous 26 vs. 20 days, p<0.0001; allogeneic 42 vs 30 days, p<0.001; respectively), IHM (CDI vs. none: autologous, 4.0 vs. 2.2%, p=0.0003; allogeneic 12.7 vs 9.2%, p=0.0008) and mean hospitalization charges (CDI vs. none: autologous $208,025 vs. $145,250, p<0.0001; allogeneic $367,415 vs $270,366 p<0.0001; respectively) were significantly higher among SCT pts with CDI ( Table 1 ). Figure 1 View large Download slide Trend of CDI in SCT recipients Figure 1 View large Download slide Trend of CDI in SCT recipients  Close modal Table 1 Pt characteristics, multivariate regression models for evaluating risk and outcomes of SCT pts with CDI  . Autologous SCT . Allogeneic SCT . . CDI (%) (N=3772) . SCT patients (%) (N=63202) . p-value . CDI (%) (N=3440) . SCT patients (N=38066) . p-value . Mean age (SE)  54.3 (0.52) 52.02 (0.27) <0.0001 45.07 (0.64) 46.57 (0.38) <0.0098 Male  2311 (61.3) 37038 (58.6) 0.1596 2188 (63.6) 21906 (57.6) 0.0005 White  2369 (77.4) 26124 (74.3) 0.1089 2199 (77.7) 23695 (78) 0.847 Comorbidities \u22651  2945 (78) 46872 (74.2) 0.05 2607 (75.8) 27712 (72.8) 0.1073 Medicare  945 (25.1) 12460 (19.8) <0.0001 310 (9.0) 4111 (10.8) 0.183 Medicaid  330 (8.8) 6818 (10.8) 0.1161 474 (13.8) 3996 (10.5) 0.0126 Private Insurance  2320 (61.6) 40209 (63.8) 0.2483 2486 (72.4) 27601 (72.7) 0.8798 Mean LOS (SE)*  26 (0.71) 20 (0.27) <0.0001* 42 (1.59) 30 (0.68) <0.0001* IHM  152 (4.0) 1330 (2.1) 0.0003 438 (12.7) 3360 (8.8) 0.0008 Charge Mean (SE)  208025 (8370.6)  145250 (4311.3)  <0.0001*  $367415 (15033)  $270366 (11835)  <0.0001*  Multivariate logistic regression model evaluating risk of CDI in SCT patients  Variable  Odds Ratio  Ref  p-value  Odds Ratio  Ref  p-value  \u226565  1.4 (0.987-1.985) Age <40 (Ref) 0.1945 0.637 (0.426-0.953)  0.0834 Male  1.25 (1.054-1.483)  Female (Ref) 0.0103  1.351 (1.157-1.576)  Female (Ref) 0.0001  Medicare  1.149 (0.878-1.502) Private (Ref) 0.0439 0.85 (0.581-1.244) Private (Ref) 0.4605 Medicaid  0.887 (0.642-1.226)  0.7673 1.269 (0.920-1.749)  0.0272 No Comorbidities  0.831 (0.650-1.063) Comorbidities \u22651 0.1406 0.829 (0.672-1.024) Comorbidities \u22651 0.082 . Autologous SCT . Allogeneic SCT . . CDI (%) (N=3772) . SCT patients (%) (N=63202) . p-value . CDI (%) (N=3440) . SCT patients (N=38066) . p-value . Mean age (SE)  54.3 (0.52) 52.02 (0.27) <0.0001 45.07 (0.64) 46.57 (0.38) <0.0098 Male  2311 (61.3) 37038 (58.6) 0.1596 2188 (63.6) 21906 (57.6) 0.0005 White  2369 (77.4) 26124 (74.3) 0.1089 2199 (77.7) 23695 (78) 0.847 Comorbidities \u22651  2945 (78) 46872 (74.2) 0.05 2607 (75.8) 27712 (72.8) 0.1073 Medicare  945 (25.1) 12460 (19.8) <0.0001 310 (9.0) 4111 (10.8) 0.183 Medicaid  330 (8.8) 6818 (10.8) 0.1161 474 (13.8) 3996 (10.5) 0.0126 Private Insurance  2320 (61.6) 40209 (63.8) 0.2483 2486 (72.4) 27601 (72.7) 0.8798 Mean LOS (SE)*  26 (0.71) 20 (0.27) <0.0001* 42 (1.59) 30 (0.68) <0.0001* IHM  152 (4.0) 1330 (2.1) 0.0003 438 (12.7) 3360 (8.8) 0.0008 Charge Mean (SE)  208025 (8370.6)  145250 (4311.3)  <0.0001*  $367415 (15033)  $270366 (11835)  <0.0001*  Multivariate logistic regression model evaluating risk of CDI in SCT patients  Variable  Odds Ratio  Ref  p-value  Odds Ratio  Ref  p-value  \u226565  1.4 (0.987-1.985) Age <40 (Ref) 0.1945 0.637 (0.426-0.953)  0.0834 Male  1.25 (1.054-1.483)  Female (Ref) 0.0103  1.351 (1.157-1.576)  Female (Ref) 0.0001  Medicare  1.149 (0.878-1.502) Private (Ref) 0.0439 0.85 (0.581-1.244) Private (Ref) 0.4605 Medicaid  0.887 (0.642-1.226)  0.7673 1.269 (0.920-1.749)  0.0272 No Comorbidities  0.831 (0.650-1.063) Comorbidities \u22651 0.1406 0.829 (0.672-1.024) Comorbidities \u22651 0.082 View Large Multivariate logistic regression model evaluating hospitalization outcomes in SCT patients with CDI #  CDI . Absence . Presence . p-value . CDI . Absence . Presence . p-value . LOS >19 days  0.382 (0.31-0.466) 1.00 (Ref) <0.0001  LOS > 27 days  0.337 (0.27-0.42) 1.00 (Ref) <0.0001 Charge > $125,091  0.483 (0.40-0.58)  <0.0001  Charge > $22,6011  0.487 (0.38-0.67)  <0.0001 IHM  0.68 (0.44-1.06)  0.089  IHM  0.661 (0.50-0.87)  0.0037 CDI . Absence . Presence . p-value . CDI . Absence . Presence . p-value . LOS >19 days  0.382 (0.31-0.466) 1.00 (Ref) <0.0001  LOS > 27 days  0.337 (0.27-0.42) 1.00 (Ref) <0.0001 Charge > $125,091  0.483 (0.40-0.58)  <0.0001  Charge > $22,6011  0.487 (0.38-0.67)  <0.0001 IHM  0.68 (0.44-1.06)  0.089  IHM  0.661 (0.50-0.87)  0.0037 SE: Standard error; *adjusted for age, race, sex, comorbidity and payer status. # Median LOS and charges used as cut-off for hospitalization outcomes View Large Conclusions The incidence of CDI among both autologous and allogeneic SCTs have remained stable over the last decade, with a slightly higher risk among allogeneic SCT pts. CDI was associated with longer hospital stay, higher charges and higher IHM for both autologous and allogeneic transplant pts. While this analysis does not permit us to directly ascribe differences in outcome to CDI alone, these data suggest that CDI has a major morbid impact in the setting of SCT, and provides a rationale for development of more effective approaches for prevention of CDI in these pt populations. Disclosures: Kaufman: Onyx: Consultancy; Celgene: Consultancy, Research Funding; Novartis: Consultancy, Research Funding; Janssen: Consultancy; Millenium: Consultancy; Merck: Research Funding. Lonial: Millennium: Consultancy; Celgene: Consultancy; Novartis: Consultancy; BMS: Consultancy; Sanofi: Consultancy; Onyx: Consultancy.",
    "topics": [
        "clostridium difficile infections",
        "hematopoietic stem cell transplantation",
        "brachial plexus neuritis",
        "transplantation",
        "dysentery",
        "infectious diarrhea",
        "length of stay",
        "tissue transplants",
        "logistic regression",
        "standard error"
    ],
    "author_names": [
        "Nishi N Shah, MBBS",
        "Ajay K. Nooka, MD, MPH",
        "Jonathan L. Kaufman, MD",
        "Daniela Casbourne, FNP-BC",
        "AOCNP",
        "Donald Hutcherson",
        "Rachael Maynard, MPH",
        "Edmund K. Waller, MD, PhD",
        "Sagar Lonial, M.D.",
        "Amelia Langston, MD"
    ],
    "author_dict_list": [
        {
            "author_name": "Nishi N Shah, MBBS",
            "author_affiliations": [
                "Winship Cancer Institute, Emory University, Atlanta, GA, USA, "
            ],
            "author_rank": 1,
            "first_author": 1,
            "last_author": 0
        },
        {
            "author_name": "Ajay K. Nooka, MD, MPH",
            "author_affiliations": [
                "Division of BMT, Winship Cancer Institute - Hematology and Medical Oncology, Emory University, Atlanta, GA, USA, "
            ],
            "author_rank": 2,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Jonathan L. Kaufman, MD",
            "author_affiliations": [
                "Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA, USA, "
            ],
            "author_rank": 3,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Daniela Casbourne, FNP-BC",
            "author_affiliations": [],
            "author_rank": 4,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "AOCNP",
            "author_affiliations": [
                "Winship Cancer Institute of Emory University, Atlanta, GA, USA, "
            ],
            "author_rank": 5,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Donald Hutcherson",
            "author_affiliations": [
                "Emory University-School of Medicine, Winship Cancer Institute-Hematology and Medical Oncology, Atlanta, GA, USA, "
            ],
            "author_rank": 6,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Rachael Maynard, MPH",
            "author_affiliations": [
                "Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA, USA, "
            ],
            "author_rank": 7,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Edmund K. Waller, MD, PhD",
            "author_affiliations": [
                "Department of Hematology and Medical Oncology, Winship Cancer Institute, Division of BMT, Emory University, Atlanta, GA, USA"
            ],
            "author_rank": 8,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Sagar Lonial, M.D.",
            "author_affiliations": [
                "Winship Cancer Institute of Emory University, Atlanta, GA, USA, "
            ],
            "author_rank": 9,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Amelia Langston, MD",
            "author_affiliations": [
                "Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA, USA, "
            ],
            "author_rank": 10,
            "first_author": 0,
            "last_author": 1
        }
    ],
    "datetime_abstract_obtained": "2022-05-26T21:38:23",
    "is_scraped": "1"
}